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To gain insight into the molecular mechanisms involved in the inherited predisposition to melanoma and associated neural system
tumours, 42 Jewish, mainly Ashkenazi, melanoma families with or without neural system tumours were genotyped for germline point
mutations and genomic deletions at the CDKN2A/ARF and CDK4 loci. CDKN2A/ARF deletion detection was performed using
D9S1748, an intragenic microsatellite marker. Allele dosage at the p14
ARF locus was analysed by quantitative real-time PCR employing
a TaqMan probe that anneals specifically to exon 1b of the p14
ARF gene. For detecting point mutations, dHPLC and direct sequencing
of the coding sequences of CDKN2A/ARF and CDK4 was used. No germline alterations in any of the tested genes were detected
among the families under study. We conclude that in the majority of Ashkenazi Jewish families, the genes tested are unlikely to be
implicated in the predisposition to melanoma and associated neural system tumours.
British Journal of Cancer (2005) 92, 2278–2285. doi:10.1038/sj.bjc.6602629 www.bjcancer.com
Published online 31 May 2005
& 2005 Cancer Research UK
Keywords: Ashkenazi Jewish melanoma families; neural system tumours; CDKN2A/ARF; CDK4; germline mutations; inherited
predisposition
                                             
Familial cutaneous malignant melanoma is a genetically hetero-
geneous condition linked to chromosome 9p21 in many, but not all
families (Hussussian et al, 1994; Greene, 1999). To date, germline
mutations in two high penetrance genes have been identified in
some of these families, CDKN2A/ARF and CDK4. The CDKN2A/
ARF gene encodes two distinct proteins, p16
INK4 and p14
ARF, the
result of alternative splicing of exons 1a and 1b, respectively. The
p16
INK4 protein, which belongs to the INK4 family of cyclin-
dependent kinase inhibitors, plays a key role in arresting cell cycle
progression at the G1 phase by inhibiting cyclins CDK4 and CDK6
and subsequently blocking their ability to phosphorylate the
retinoblastoma protein Rb (Chin et al, 1998). The p14
ARF protein is
also involved in cell cycle regulation by interacting with different
substrates in the p53 pathway (Pomerantz et al, 1998), and by
binding to MDM2, also in the Rb pathway with resultant cell cycle
arrest in both G1 and G2 phases (Xiao et al, 1995; Weber et al,
1999; Momand et al, 2000). In all, 20% of melanoma families were
found to harbour genetic alterations at the CDKN2A/ARF gene
(Goldstein, 2004). The other gene involved in familial predisposi-
tion to melanoma, CDK4 is a proto-oncogene that promotes cell
cycle progression by phosphorylating the Rb protein. Germline
mutations in CDK4 were detected in three melanoma families
(Zuo et al, 1996; Soufir et al, 1998).
The familial clustering of both melanoma and neural system
tumours (NST) was first reported in 1993 by Kaufman et al (1993)
in a single family with eight family members over three
generations who were diagnosed with cutaneous melanoma,
cerebral astrocytoma or both. Azizi et al (1995) surveyed 904
melanoma Jewish-Israeli patients for the occurrence of NST in
their family pedigrees. Melanoma-affected members within
families, as well as first and second-degree relatives, were found
to be at an increased risk for developing NST. A total of 15 families
with a clustering of melanoma and a variety of NST were
identified, and 10 patients with two primary tumours, melanoma
and NST, primarily meningioma were described (Azizi et al, 1995).
Similar familial clustering of melanoma and NST was described
in French (Bahuau et al, 1997) and Finnish families (Paunu et al,
2002). Recently, melanoma and NST association was confirmed by
epidemiological and population-based studies in Scandinavia
(O’Neill et al, 2002; Hemminki et al, 2003; Nielsen et al, 2004).
The familial clustering of melanoma and NST has been recognised
and designated as the Melanoma and Neural System Tumour
syndrome (MM-NST) (OMIM # 155755), and in a small subset of
melanoma-NST kindreds germline mutations, mainly deletions
affecting the CDKN2A/ARF gene and cosegregating with both
tumours, were described.
In the present study, 42 Jewish, mainly Ashkenazi, melanoma
families with (n¼24) or without NST (n¼18) were genotyped for
germline sequence alterations in the CDKN2A/ARF and CDK4
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melanoma and NST is the largest analysis reported thus far.
MATERIALS AND METHODS
Patients
Jewish families with a history of melanoma and NST were recruited
to the study. The inclusion criteria (based on OMIM’s definition)
were a minimum of two cancers in the pedigree, one being
melanoma and the other NST, or an individual harbouring both
tumours.
Additional 18 Jewish melanoma families without NST, having at
least two or more individuals with melanoma, or multiple
melanomas in a single family member – as minimal inclusion
criteria – were also included.
The families had been recruited between the years 1997 and
2003. The study had been approved by the Institutional Ethics
Committee of the Sheba Medical Center, Israel. All participants
signed a written informed consent prior to being enrolled in the
study. Demographic details, including country of birth of the
probands, their parents and grandparents, were collected using a
self-response questionnaire. Classification to ethnic groups was
done according to the country of birth of the grandparents on
both the maternal and paternal sides, provided that one or both
parents were either from the same origin, or Israeli-born. Families
with both sets of grandparents from Eastern and Central
European countries were classified as Ashkenazi. Families
originating from Spain, North-Africa, Balkans, or Iraq, Iran,
Yemen and Egypt were classified as Sephardic. Every effort has
been made to confirm the correct cancer type for affected
members based on pathology report, patients’ medical charts,
operation reports and death certificate. When these were not
available, information regarding tumours that was obtained by
history from several family members but not confirmed by a
pathology report was designated as histological type not specified.
A dermatological examination assessing skin phenotype, atypical
mole syndrome (AMS) score (Newton Bishop et al, 1994) and
signs of dermato-heliosis was performed by one of three
participating dermatologists and 10ml of venous blood samples
were withdrawn for DNA extraction.
Genetic alterations detection
DNA preparation Genomic DNA was extracted from peripheral
blood leucocytes using the Puregene
s Genomic DNA Isolation Kit
(Gentra Systems, Minneapolis MN, USA), using the manufacturer’s
recommended protocol.
Mutation analysis For detecting CDKN2A/ARF and CDK4 gene
coding region sequence alterations, exons 1a,1 b and 2 of
CDKN2A/ARF and exon 2 of CDK4 were screened by dHPLC
(denaturing high performance liquid chromatography), by using
PCR and dHPLC analysis conditions previously described (Laud
et al, 2003). Briefly, PCR was carried out in a final volume of
20ml containing 100ng genomic DNA, 1  HotStar Taq DNA
Polymerase buffer with 1.5mM MgCl2 (Qiagen), 4pmoles of each
primer, 1UI HotStar Taq DNA Polymerase (Quiagen) and 2.5mM
dNTPs. For PCR amplification of each exon, a touch down
protocol was used as follows: initial denaturation and HotStar Taq
Polymerase activation at 951C for 15min; six cycles of 30s at 951C,
30s at 661C (the annealing temperature decreasing by 21C at every
two cycles), 30s at 721C; followed by 40 cycles of 30s at 951C, 30s
at 601C and 30s at 721C. Heteroduplex analyses were carried out
on an automated dHPLC instrument (WAVE, Transgenomic, CA,
USA). DNA samples with known germline mutations at CDKN2A/
ARF locus were used as positive controls.
Samples displaying abnormal profiles were subsequently bi-
directionally sequenced using the BigDyet Terminator sequencing
kit (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions on an ABI Prism 377 instrument
(Applied Biosystems, Foster City, CA, USA).
CDKN2A/ARF deletion detection Since CDKN2A/ARF deletions
were previously identified in melanoma-NST families (Bahuau
et al, 1998, Randerson-Moor et al, 2001), deletions were sought
only in this subset of families (n¼24). Deletion genotyping was
performed using the D9S1748 microsatellite marker located
adjacent to CDKN2A exon 1b. The PCR amplifications were
carried out in a final volume of 25ml, the reaction mix containing:
1  HotStar Taq DNA polymerase buffer with 1.5mM MgCl2
(Qiagen, Chatsworth, CA, USA), 1UI HotStar Taq DNA polymer-
ase (Qiagen), 4pmoles of each primer and 0.2mM dNTPs. Primer
sequences are available through The Genome Database (http://
www.gdb.org). The forward primer was fluorescently labeled with
the 6-FAM at its 50 extremity. The PCR products were loaded on
a 6%/7 M urea denaturing polyacrylamide gel in an ABI Prism 377
(Applied Biosystems, Foster City, CA, USA) device along with the
ROX 350 (Applied Biosystems, Foster City, CA, USA) internal
marker standard. Genotypes were analysed using the GeneScan
software (Applied Biosystems, Foster City, CA, USA). Since the
homozygous status could possibly be due to the loss of an allele,
homozygous samples were further analysed for allele dosage
(Barrois et al, 2004) at the p14ARF locus by quantitative real-time
PCR using an ABI Prism 7700 instrument (Applied Biosystems,
Foster City, CA, USA). A TaqMan probe that anneals specifically to
the exon 1b of the p14ARF gene, marked with a fluorescent
reporter dye (FAM) and a quencher dye (TAMRA), was used. By
calculating the ratio initial copy number of p14ARF/initial copy
number of GAPDH, we obtained the normalized gene dose. The
PCR was performed in triplicate for each sample in a final volume
of 50ml, the reaction mix containing for the GAPDH gene 1 
TaqMan Universal Master Mix (Applied Biosystems, Foster City,
CA, USA), 15pmoles of each primer and probe and 25ng DNA. For
the exon 1b of CDKN2A, same quantities were used, with the
exception of the TaqMan Universal Master Mix which was replaced
by 1  TaqMan PCR Core Reagent Buffer (Applied Biosystems,
Foster City, CA, USA), 2.5mM dNTPs, 5% glycerol, 5mM MgCl2
and 1.25UI AmpliTaqGold DNA polymerase (Applied Biosystems,
Foster City, CA, USA). Amplification conditions were: 2min at
501C, 10min at 951C (20min for p14ARF) followed by 40 cycles of
15s at 951C and 1min at 601C. We used as positive control the
haploid cell line HL60 kindly provided by Juliette Moor and Julia
Newton Bishop from Genetic Epidemiology Division, Cancer
Research UK, St James’s University Hospital, Leeds, UK (Randerson-
Moor et al, 2001).
RESULTS
Clinical features of the study participants
The study population included (a) 25 probands and 11 unaffected
relatives from 24 families with pedigrees displaying cutaneous
melanoma and NST and (b) 20 probands from 18 melanoma
families without NST, among them 13 families with pedigrees
containing two or more melanoma-affected individuals and five
families containing individuals with multiple melanomas. Nota-
bly, the clinical features of two families (#107 and #121) have
already been described earlier (Azizi et al, 1995). Distribution by
tumour type, number of tumours and family affiliation is
presented in Tables 1, 2 (melanoma-NST families) and 3 (familial
melanoma).
Among the melanoma-NST pedigrees, in 10/24 (42%) families
there were two melanoma or two NST cases, and in the others in
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family (Table 1). The male:female (M:F) ratio among the affected
cases was 1. The melanoma and NST were diagnosed at the age
range of 22–74 years and 10–86 years, respectively. Of the 24
families in this subgroup, 22 were of Ashkenazi origin, one out of
24 was Sephardic (#107), and one out of 24 heterogeneous (#121).
Major phenotypic features of the patients, available in 13 out of
25 probands, were variable with no specific pattern. Additional
cancers that were reported in this series included colon cancers in
four families; breast cancer in three families; lung cancer in two
families; liver cancer in two families; and renal, gastric, laryngeal,
pleural and nonmelanoma skin cancer each in one family (Table 2).
Examples of pedigrees showing melanoma families with NST are
presented in Figure 1.
Among the 18 melanoma families without NST (Table 3), the
M:F ratio among the melanoma patients was 1:2, and the age
at diagnosis was in the range of 25–88 years. Of 18 families in
this series, 17 were of Ashkenazi origin. Family #321 was of
heterogeneous Romanian (Ashkenazi)/Turkish-Greek (Sephardic)
origin. Major phenotypic features of the melanoma patients, not
available for two out of 20 probands included dermato-heliosis and
solar keratosis (15 out of 18), freckles (15 out of 18) and AMS X2
(seven out of 18). Additional cancers that were reported in this
series included nonmelanoma skin cancer in three families;
prostate cancer in three; breast cancer in five; pancreatic cancer
in one; transitional cell carcinoma in one and lymphoma in one.
Examples of pedigrees showing melanoma families without NST
are presented in Figure 2.
Table 1 The distribution of melanoma-NST pedigrees according to
number of tumours
No. of tumours
a Family # Total n (%)
NST 2
and MM 2
120 1 (0.5)
NST 2
and MM 1
116, 122, 113 3 (12.5)
MM 2
and NST 1
105, 109, 110
114, 118, 101
6 (25.0)
MM 1
and NST 1
112, 117, 119
102, 103, 104
106, 108, 111
115, 123, 124
107, 121
14 (58.0)
Total 24 (100.0)
aMM¼melanoma, NST¼neural system tumours.
Table 2 Distribution of melanoma-NST pedigrees by tumour type and family affiliation
Proband Affected relatives Unaffected relatives
Family # DNA#
MM (
a) NST (
b)
Additional
cancers MM NST (
b) Additional cancers
(n¼24) (n¼25) Gender
(Age at
diagnosis)
(Age at
diagnosis) DNA# Gender Age
116 115 F 68 64 (c) BCC (66) — Mother Lung (uncle) 139 F 35
SCC (69) (47) (x)
120 218 M 51 51 (c) BCC — — Pleura (father) — — —
219 M — 16 (b) brother
122 221 M 51 51 (g) — — Father (84) (x) Colon (mother) — — —
110 5 M 52 45 (f) — Sister (50) — — 4 M 15
2F2 0
3M2 1
105 88 F 58 68 (c) — — — — — — —
67
113 165 M 57 19 (x) BCC — — Lung (mother) 194 M 65
25 Liver (cousin)
112 169 F 63 63 (e) — — — — — — —
117 153 F 55 56 (c) — — — Breast (mother) — — —
109 27 M 67 — — Brother (a) — 67 M 45
66 F 40 Daughter
114 73 F 22 — Mother (48) Mother (51,61) (e) — 41 M 14
118 47 M 23 — Mother (43) Mother (51) (b) — — — —
101 154 M 32 BCC (37) Mother (65) Mother (68) (f) — 185 F 45
119 — — — — Aunt Sister (d) Breast (sister, mother) 12 M 53
102 109 M 67 — — Grandson (24) (e) — 133 F 45
103 6 M 40 — — Mother (71) (a) Colon (mother) BCC/SCC Larynx
(father) Liver (grand-mother)
—— —
104 13 F 67 Colon — Brother (a) Colon (brother) — — —
106 160 M 74 — — Father (68) (x) — 166 M 75
108 131 M 67 — — Brother (57) (x) — — — —
111 113 F 66 — — Mother (x) — — — —
115 137 F 24 — — Grand-mother (86) (x) — — — —
123 222 F 56 — — Father (84) (x) Colon (mother) — — —
124 223 M 36 — — Cousin (30) (x) Renal (father) Gastric (aunt) — — —
107 83 F 43 — — Daughter (10) (h) — — — —
121 220 F 37 — — Grand-father (x) Breast (mother) — — —
aMM¼melanoma.
bNST¼neural system tumours, (a)¼glioblastoma multiforme, (b)¼oligodendroglioma, (c)¼meningioma, (d)¼glioma, (e)¼neurilemmoma,
(f)¼malignant peripheral schwannoma, (g)¼brain germinoma, (h)¼medulloblastoma, (x)¼NST, pathologic type unspecified.
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genes for point mutations
Overall, nine samples displayed different chromatographic pro-
files. Sequence analyses revealed a G to A transition at position 442
leading to a missense mutation at codon 148 (Ala148Thr) in all
nine patients: patients #5, #83 and #115, all unrelated, among the
melanoma-NST families (Table 4); and patients #15, #111, #114,
#116, #124, #134, all unrelated among the melanoma families
without NST (Table 5).
#47
#3 #2 #4
#5
Ala148Thr
#73
#41
 #27
#67 #66 #154
#115
Ala148Thr
#139
Figure 1 Representative pedigrees of six Jewish families with melanoma and neural system tumours (NST). Family codes of presented pedigrees (from
left-to-right, top-to-bottom) – #110, #116, #118, #114, #109, #101. Striped squares and circles indicate male and female subjects with melanoma,
respectively. Crossed symbols indicate individuals with neural system tumours and upper quarter filled symbols represent the presence of other tumours.
Sample DNA code number and sequence alterations are indicated.
Table 3 Distribution of Pedigrees of melanoma families without neural system tumours, by tumour type and family affiliation
Patient Affected relatives
Family # (n¼18)
DNA# (n¼20) Gender MM (
a) Additional cancers MM Additional cancers
(Age at diagnosis) (Age at diagnosis)
302 104 F 74 — Cousin (72) —
303 103 M 49
(7 primary MM)
BCC
SCC
Brother —
305 100 F 74 BCC (75) Nephew —
309 112 F 52 — — Pancreas (father)
310 111 F 45
64
—— —
311 105 F 48 — Sister Breast (mother)
312 119 M 68 Prostate (68) Mother (83)
Brother (65)
Daughter (19)
—
317 116 F 60 — Grandmother —
319 114 M 36 — Cousin —
321 15 F 25 — Grandfather (61)
Uncle
TCC (cousin)
Breast (grandmother)
322 124 M 66 Prostate — Breast (mother)
67 (67)
325 78 F 61
61
Breast (56) — —
79 F 33 daughter
327 121 M 86 — — —
135 F 88 sister
329 122 F 47
62
— — Lymphoma (mother)
330 140 F 67
71
— Daughter —
335 134 F 25 Breast Uncle
Grandfather
Breast (mother)
BCC (father)
337 141 M 64
65
Prostate (56) — —
338 138 F 52
53
BCC (47) Daughter (32) —
aMM¼melanoma.
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A total of 30 individuals among the melanoma-NST families
were genotyped using the D9S1748 microsatellite marker, located
adjacent to exon 1b of CDKN2A/ARF gene on chromosome 9p21.
A total of 12 samples displayed a heterozygous status, that is,
two alleles without genomic deletion (Table 4); And 18 samples
displaying homozygous profiles for this locus were selected for
further analysis, since the homozygous status could indicate the
loss of an allele by a large deletion encompassing exon 1b. Gene
dosage for these samples, as well as six samples not analysed for
the D9S1748 microsatellite marker, showed no deletions, therefore,
all individuals presented two alleles (Table 4).
DISCUSSION
In the present study, no bona fide pathogenic germline alterations
were identified in the CDKN2A/ARF and CDK4 loci among 42
Jewish, primarily Ashkenazi Israeli families, with a seemingly
inherited predisposition to cutaneous melanoma, and in some,
clustering of melanoma with NST, for deletions and point
mutations in the CDKN2A/ARF and CDK4 loci. The only sequence
variation identified in nine DNA samples was G to A transition at
position 442 leading to a missense mutation at codon 148
(Ala148Thr). The Ala148Thr missense mutation is considered as
a polymorphism based on several observations: it has been
previously reported in individuals from the general, average risk,
population in ethnically diverse groups: 8% of the Jewish
population (Yakobson et al, 2000), 4% of the population in Utah
(Kamb et al, 1994) and 5% in the UK population (Bertram et al,
2002). Furthermore, this missense mutation did not segregate
with the phenotype in familial melanoma (Hussussian et al, 1994;
Harland et al, 1997), and is situated outside the critical four
ankyrin repeat domains of p16, and thus does not appear to have
any effect in vitro on binding to CDK4 (Ranade et al, 1995;
Lilischkis et al, 1996; Harland et al, 1997). Ala148Thr was further
analysed in twin studies as a candidate low penetrance poly-
morphism enhancing the risk of melanoma by increasing AMS
score (Zhu et al, 1999). However, the rate of this polymorphism
in families with atypical mole phenotype was similar to general
population (Bertram et al, 2002). Thus, Ala148Thr is considered a
p16 polymorphism and not a pathogenic mutation.
Genetic mutations at the CDKN2A gene have been identified
in 20% of melanoma families, most of these in exons 1a and 2
(Goldstein, 2004). Several studies also implicated the ARF gene as
underlying melanoma predisposition. A 16bp insertion in exon
1b, which affects the function of p14 but not p16, was described
in a patient with multiple primary melanomas (Rizos et al, 2001).
A splice site mutation in exon 1b, which results in p14
haploinsufficiency, was also reported in two affected persons
from melanoma kindred (Hewitt et al, 2002). The negative
mutation detection results in the present study among Jewish
Ashkenazi melanoma families are not in line with the expected
mutation rate, based on previously reported data in non-Jewish
populations.
Among families with melanoma-NST association, the loss of
function of CDKN2A/ARF can be a predisposing factor. Segrega-
tion analysis of two melanoma-NST French families showed
hemizygous germline deletion that ablated CDKN2A/ARF gene
(Bahuau et al, 1998). Analysis of 11 families with two or more cases
of glioma revealed a hemizygous germline deletion in CDKN2A
in one family with both glioma and melanoma (Tachibana et al,
2000). In another melanoma family with NST (mainly astro-
cytoma), deletion was found in the CDKN2A/ARF exon 1b. The
deletion, leading to loss of ARF function, did not affect the coding
region of p16 protein (Randerson-Moor et al, 2001). Finally, a
splice site substitution mutation trimming CDKN2A exon 2 and
severely affecting both p16INK4A and p14ARF was described in
a family with melanomas, neurofibromas and multiple dysplastic
nevi (Petronzelli et al, 2001). Constitutional CDKN2A locus
alterations, somatic point mutations and deletions at CDKN2A
were identified in NST (Ueki et al, 1996; Bostrom et al, 2001;
Ghimenti et al, 2003). Evidence was presented that deletion in ARF
may be the underlying cause in the development of melanoma and
NST (Randerson-Moor et al, 2001).
Yet, the lack of mutations at the genes analysed in this series
of melanoma families with NST is commensurate with data from
other melanoma-NST families genotyped for mutations: in a family
with melanoma and optic nerve glioma, no mutations were
identified in the CDKN2A gene (Alao et al, 2002). Analysis of
Swedish patients with multiple primary melanomas and NST was
negative for the CDKN2A founder mutation 113insArg, which
usually explains all CDKN2A-associated familial melanoma in
Sweden (Nielsen et al, 2004).
It is unlikely that the familial clustering of melanoma and
NST is due to chance, as both tumours are relatively rare cancers
in Israel, with age standardised incidence rates of 7.7 and 8.4
per 10
5, respectively, in female subjects, and 7.6 and 10.3 per 10
5,
respectively, in male subjects (Azizi et al, 1995). All the melanoma
families with NST in the present series withstand the OMIM
criteria for the melanoma-NST syndrome. Yet, without identifying
a mutation, cosegregating within the current series of families
with both melanoma and NST, we cannot unequivocally
determine the proportion of families that truly represent
melanoma-NST syndrome. However, 10 families (42% of the
series), having at least two melanoma or two NST probands, are
strongly suggestive of an inherited predisposition for developing
melanoma and NST.
Lack of germline mutations in the CDKN2A/ARF and CDK4 loci
has been recently reported by Loo et al (2005) among 22 Ashkenazi
Jewish families with an apparent inherited predisposition to
melanoma. Taken together with the data reported herein, it
appears that in over 60 Ashkenazi Jewish melanoma families, no
germline alteration in CDKN2A/ARF and CDK4 loci underlie the
#119
#134
Ala148Thr
#78
#79
#15
Ala148Thr
Figure 2 Representative pedigrees of four Jewish melanoma families
without neural system tumours. Family codes of presented pedigrees (from
left-to-right, top-to-bottom) – #312, #321, #325, #335. Striped squares
and circles indicate male and female subjects with melanoma, respectively.
Upper quarter filled symbols represent individuals with other tumours.
Sample DNA code number and sequence alterations are indicated.
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sTable 4 Mutation detection analysis in p16, p14 and CDK4 genes of melanoma-NST pedigrees (n¼24)
Family #
(n¼24)
DNA #
(n¼36)
P16 sequencing
analysis
P14 deletion
analysis by
D9S1748
Quantative
TaqMan analysis
of p14
p14
sequencing
CDK4
sequencing
101 154 WT Hmz 2n WT WT
185
a WT Htz ND WT WT
102 109 WT Htz ND WT WT
133
a WT Hmz 2n WT WT
103 6 WT Hmz 2n WT WT
104 13 WT Htz ND WT WT
105 88 WT Hmz 2n WT WT
106 160 WT Htz ND WT WT
166
a WT Htz ND WT WT
107 83 Ala148Thr Hmz 2n WT WT
108 131 WT Htz ND WT WT
109 27 WT Htz ND WT WT
66 WT Hmz 2n WT WT
67
a WT Hmz 2n WT WT
110 5 Ala148Thr Hmz 2n WT WT
4
a WT Hmz 2n WT WT
2
a WT Hmz 2n WT WT
3
a WT Htz ND WT WT
111 113 WT Hmz 2n WT WT
112 169 WT Htz ND WT WT
113 165 WT Hmz 2n WT WT
194
a WT Hmz 2n WT WT
114 73 WT Hmz 2n WT WT
41
a WT Htz ND WT WT
115 137 WT Hmz 2n WT WT
116 115 Ala148Thr Hmz 2n WT WT
139
a WT Hmz 2n WT WT
117 153 WT Hmz 2n WT WT
118 47 WT Htz ND WT WT
119 12
a WT Htz ND WT WT
120 218 WT ND 2n WT WT
219 WT ND 2n WT WT
121 220 WT ND 2n WT WT
122 221 WT ND 2n WT WT
123 222 WT ND 2n WT WT
124 223 WT ND 2n WT WT
aUnaffected relatives.
Table 5 Mutation detection analysis in p16, p14 and CDK4 genes of pedigrees of melanoma families without neural system tumours (n¼18)
Family #
(n¼18)
DNA #
(n¼20)
P16 sequencing
analysis
P14 deletion
analysis by
D9S1748
Quantative
TaqMan analysis
of p14
p14
sequencing
CDK4
sequencing
302 104 WT ND ND WT WT
303 103 WT ND ND WT WT
305 100 WT ND ND WT WT
309 112 WT ND ND WT WT
310 111 Ala148Thr ND ND WT WT
311 105 WT ND ND WT WT
312 119 WT ND ND WT WT
317 116 Ala148Thr ND ND WT WT
319 114 Ala148Thr ND ND WT WT
321 15 Ala148Thr ND ND WT WT
322 124 Ala148Thr ND ND WT WT
325 78 WT ND ND WT WT
79 WT ND ND WT WT
327 121 WT ND ND WT WT
135 WT ND ND WT WT
329 122 WT ND ND WT WT
330 140 WT ND ND WT WT
335 134 Ala148Thr ND ND WT WT
337 141 WT ND ND WT WT
338 138 WT ND ND WT WT
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should be pointed out is that germline alterations in noncoding
regions such as intronic and promoter sequences not screened in
the present and in previous studies cannot be ruled out as
contributing to familial melanoma.
In conclusion, in the majority of Ashkenazi Jewish families with
an inherited predisposition to melanoma with or without NST,
CDKN2A/ARF and CDK4 loci are unlikely to be implicated in the
predisposition to melanoma and the associated neural system
tumours.
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